Treatment of relapsed and refractory Hodgkin Lymphoma

Despite the high first line cure rates in patients with Hodgkin Lymphoma (HL) still 10-20% of patients suffer from relapsed or refractory disease. High dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research